A study published in Diabetes, Obesity and Metabolism found that obesity rates among type 1 diabetes patients increased for all age groups and ethnicities from 2008 to 2023. GLP-1 receptor agonist use also rose sharply, with a sevenfold increase in severely obese youth with type 1 diabetes between 2008-11 and 2020-23.
A study found no increased risk of suicidal events among adults taking GLP-1 receptor agonists for diabetes or obesity, but continued monitoring is warranted to identify at-risk patients. The findings ease concerns about these potential adverse effects, allowing extended use of GLP-1 RAs.
A cohort study found no significant association between preoperative GLP-1 RA use and short-term postoperative aspiration pneumonia. The study suggests reassessing preoperative withholding guidelines for GLP-1 RAs. Researchers hope this finding can help alleviate growing concerns about adverse effects of these medications after surgery.
A synthetic retinoic acid-inducible gene I (RIG-I) agonist RNA has been shown to induce innate immune signaling and death of hepatocellular carcinoma cells in vitro. The addition of recombinant interferon-b potentiated this cell death, suggesting a potential new mechanism for treating patients with liver cancer.
Sodium-glucose cotransporter-2 inhibitors and GLP-1RAs show reduced risk of moderate/severe COPD exacerbations compared to dipeptidyl peptidase 4 inhibitors. This finding may inform glucose-lowering medication prescribing for patients with type 2 diabetes and active COPD.
Researchers at Tokyo University of Science have found that opioid delta-receptor agonists can alleviate stress-induced IBS symptoms in a validated mouse model by targeting the central nervous system. The study suggests that these drugs could provide a more definitive solution for IBS with minimal adverse effects.
A systematic review and network meta-analysis of 601 trials revealed that SGLT2 inhibitors were more cardioprotective in older adults, while GLP-1 receptor agonists offered greater benefits to younger patients. These findings suggest personalized treatment approaches for type 2 diabetes based on age and sex.
A cohort study found that patients without type 2 diabetes had higher discontinuation rates and lower reinitiation rates of GLP-1 receptor agonist therapy. Inequities in access and adherence to effective treatments exacerbate disparities in obesity.
The study found a significant increase in obesity drug prescriptions from 0.76 million in July 2017 to 1.5 million in February 2024, mirroring rising public online search activity for semaglutide and tirzepatide. This correlation highlights the real-time association between public awareness and prescription trends.
A new microdosing approach using low doses of buprenorphine has been tested on patients with opioid use disorder, but most found it ineffective. The study, which included 126 participants, showed that only 34% were able to work up to a full dose of buprenorphine.
A large population-based analysis found that genetic variants in the GLP1R gene are associated with cardiometabolic traits and behavioral changes, such as risk-taking behavior and anxiety. These findings suggest that any observed behavioral changes with GLP1RA medications are unlikely to be a direct result of the medication.
Researchers at Nagoya University found that stimulating CB2 with JWH 133 improved cognitive function and reduced neuroinflammation in AD mouse models. The study suggests that CB2 is a potential therapeutic target for Alzheimer's disease, providing a cost-effective alternative to existing treatments.
A cohort study found that insurance plan type and structure play a crucial role in determining access to semaglutide for adults with obesity. The findings suggest that targeted interventions at the insurance level could improve equity in obesity treatment access.
A cross-sectional study found that websites selling compounded glucagon-like peptide-1 receptor agonists often misinformed potential consumers about the medications' safety, efficacy, and FDA approval status. The study highlights the need for increased transparency and regulation in the online advertising of these medications.
A new study reveals that delta opioid receptor agonist KNT-127 has a rapid and effective antidepressant effect with minimal side effects. The research highlights the molecular mechanisms underlying its action, including mTOR signaling pathways and Akt activation in the medial prefrontal cortex.
A large international study of GLP1-RA users and dipeptidyl peptidase-4 inhibitors (DPP-4i) found no evidence that GLP1-RA use is associated with an increased risk of thyroid cancer. The study, published in the Thyroid journal, analyzed data from 92,497 GLP1-RA users and 2,484,408 DPP-4i users.
Researchers developed a method to distinguish between similar odours by detecting small electrical changes in olfactory receptors. This innovation enables more precise sensors for industrial applications, such as odour screening.
Adult obesity trends in the US have declined for the first time in more than a decade, according to recent data. The South region experienced the largest decreases in body mass index and obesity prevalence, despite also facing high COVID-19 mortality rates among obese individuals.
A cohort study found that nearly half of participants who consumed alcohol at baseline decreased their alcohol use after initiating anti-obesity medication treatment. The medications, such as naltrexone and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), may have properties that lead to reduced cravings for alcohol.
The discontinuation of GLP-1 RAs has significant clinical implications, including reduced glucose control and increased cardiovascular risk. Long-term adherence to these therapies is crucial for optimal patient outcomes.
A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.
A cross-sectional study found a significant increase in GLP-1 receptor agonist (RA) use as anti-obesity medications from 2022 to 2023. Meanwhile, the rate of metabolic bariatric surgery decreased by 25.6% during the same period. These findings suggest a potential shift in treatment strategies for obesity management
The use of GLP-1 receptor agonists (GLP-1RAs) and SGLT2 inhibitors in people with type 1 diabetes has significantly increased between 2010 and 2023. This trend is driven by their benefits in weight management and cardiorenal protection, but caution is advised due to concerns about euglycemic diabetic ketoacidosis.
Two studies found that bariatric surgery is more cost-effective in the long term compared to GLP-1 RA weight loss drugs alone. Combining both treatments is even more cost-effective. The use of GLP-1 RA before surgery appears safe and may be a novel approach to treating obesity.
A new study found that people with opioid or alcohol use disorder who take Ozempic or similar medications have a lower rate of opioid overdose and alcohol intoxication. The medication, which treats diabetes and weight-related conditions, may also alter the brain's reward-response pathways associated with substance use.
A new study found that GLP1 receptor agonists reduce the risk of suicidal ideation or attempts in adolescents with obesity. The treatment, compared to lifestyle intervention, showed a favorable psychiatric safety profile and potential avenues for future research.
Researchers from Kumamoto University discovered that prostaglandin receptors in the uterus enhance decidualization, a crucial process for successful pregnancy. This finding opens the door to developing new fertility treatments targeting these receptors.
A major review by the Cochrane Tobacco Addiction Group identifies three effective ways to stop smoking: counseling, bupropion, and nicotine replacement therapy. The study found that combining these strategies with behavioral support yields the best results for quitting smoking.
A cohort study found no association between GLP-1 receptor agonist use and increased risk of suicide death or related disorders in patients with type 2 diabetes. The study included mostly patients with type 2 diabetes.
A North Carolina State University study found that only 12% of organizations providing residential opioid substance use services are licensed by the state. Only a quarter allow patients to access proven opioid agonist treatment (OAT), which has better outcomes and cuts overdose deaths in half.
Researchers have developed a novel nanoparticle drug-delivery system to activate an immune pathway in combination with tumor-targeting agents, showing promising results in treating pancreatic cancer. Eight out of nine mice tested experienced tumor improvements, including two complete responses.
A new study found that semaglutide significantly reduces major adverse cardiac events, including heart attacks and strokes, among overweight individuals with cardiovascular disease. The medication also shows similar benefits for people with pre-existing heart failure, regardless of type or severity.
Researchers found GLP-1 receptor agonists lower risks of certain obesity-associated cancers in patients with type 2 diabetes, suggesting potential benefits for cancer prevention in high-risk populations. The study provides preliminary evidence supporting further preclinical and clinical studies to prevent specific obesity-linked cancers.
A study published in JAMA Ophthalmology found an association between semaglutide and nonarteritic anterior ischemic optic neuropathy, a condition that can cause vision loss. The observational study suggests caution when prescribing semaglutide to patients at risk of this condition.
A randomized clinical trial found that combining exercise with glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment was the most effective weight loss strategy while preserving bone health. In contrast, GLP-1RA treatment alone reduced bone mineral density at clinically relevant sites.
In individuals with a diabetes duration of 10 years or less, bariatric metabolic surgery was associated with greater weight loss and reduced mortality compared to first-generation GLP-1RAs. No differences were observed between treatment modalities in patients with longer diabetes duration.
The study found a substantial increase in glucagon-like peptide-1 receptor agonist (GLP-1RA) dispensing among adolescents and young adults between 2020 and 2023. This trend is particularly notable for females, emphasizing the need for targeted education on sex-specific safety risks, such as concerns during pregnancy.
A novel combination of two existing drugs has been discovered to eradicate AML cancer cells in lab-based tests, offering hope for patients diagnosed annually with the disease. The treatment, pairing venetoclax with a STING agonist, showed high promise in AML samples driven by a mutated p53 protein, a type of AML generally harder to treat.
A recent study found that preoperative GLP-1 receptor agonist use is not associated with an increased risk of postoperative respiratory complications. The results suggest liberalizing withholding guidelines for these medications may be beneficial.
A new study estimates that opioid dependence in Scotland has remained relatively stable since 2014/15, affecting 1.3% of the adult population aged 15-64. The prevalence of opioid dependence among those aged 50-64 increased by 2,800, while those aged 15-34 decreased by 5,100.
Research has shown that dulaglutide, a diabetes drug, can reduce depressive-like behaviors in mice. The study identified four major pathways involved and linked markers of depression to lipid metabolism and tryptophan metabolism. This new perspective may facilitate the use of dulaglutide as a potential therapeutic strategy for depression.
A study published in JAMA Surgery found that 56% of patients using GLP-1 RAs had significant gastric contents on ultrasound before elective procedures, despite adequate fasting. The study suggests that conventional fasting times may need to be reexamined for this patient subset.
A new study published in the American Heart Association journal Hypertension found that tirzepatide significantly lowered systolic blood pressure levels in nearly 500 adults with obesity. The results suggest treating obesity with this weight loss medication may be an effective strategy for preventing or treating high blood pressure.
Only 4.1% of hospital encounters for opioid overdoses led to opioid agonist therapy (OAT) initiation within a week of discharge from hospital, highlighting missed opportunities to prevent future mortality and morbidity related to opioid use disorder. Studies show that prompt OAT initiation in the emergency department is crucial to redu...
A Northwestern University study found that nearly two-thirds of patients discontinue or change their medication within a year, highlighting the need for better understanding of barriers to treatment adherence. The high discontinuation rate for GLP-1 RAs may be due to gastrointestinal side effects.
A large study of 91,460 mother-offspring pairs found no link between prenatal corticosteroid and beta-2 adrenergic agonist exposure and offspring neurodevelopmental issues. The findings suggest these medications are safe for pregnant individuals with asthma.
Researchers at UC Irvine issue a warning that GLP-1RA's may be dangerous for children due to the risk of nutrient imbalance and abuse. The team notes that children need energy and sufficient calories for growth and development, and any change in their diet and exercise balance can have long-term health consequences.
The study reveals the molecular mechanism by which ABCC4 recognizes broad-spectrum substrates, providing a structural basis for rational design of platelet antagonists targeting ABCC4. The research also elucidated the molecular mechanism of ABCC4 in binding and transporting platelet agonists and antagonists.
A new study found that higher doses of oral semaglutide improved regulation of blood sugar levels and weight loss compared to lower doses. Participants who received the 25mg and 50mg doses lost an average of 17.5 pounds, nearly twice as much weight loss as those who took the lowest dose.
Researchers discuss the potential of glucocorticoid-induced TNFR-related protein (GITR) as a target for cancer immunotherapy. Preclinical studies have shown potent anti-tumor efficacy, but clinical trials have yielded inconsistent results due to complexities in immune responses and antibody structure.
A recent Finnish register-based study found no association between inhaled beta-2 agonist use and reduced risk of Parkinson's disease. Accumulation of alpha-synuclein protein is a key factor in the disease. The study controlled for age, sex, and comorbidities to rule out confounding factors.
Researchers at Kanazawa University used high-speed atomic force microscopy to study the TRPV1 protein's structural fluctuations in response to stimulating and suppressing ligands. They found that ligand binding increases conformational fluctuations, while suppression decreases them.
KNT-127 exhibits anti-stressing and anti-depressant effects in mice, improving social interaction and reducing stress-induced hormone levels. The agent suppresses neuronal inflammation and newborn death without affecting neurogenesis.
Researchers at Temple University and Johns Hopkins University found that brain-derived neurotrophic factor (BDNF) loss underlies post-myocardial infarction heart failure. BDNF levels can be replenished therapeutically, abolishing damage to heart tissue and enabling recovery.
Researchers at Moffitt Cancer Center have discovered a combination strategy that targets the STING signaling pathway, resulting in improved antitumor activity. Inhibiting methylation increases STING expression and activates immune cells, leading to enhanced antitumor immunity.
A study found that over 80% of American adults with type 2 diabetes meet the criteria to use GLP-1 RAs or SGLT2is, but only a small percentage are using them. The medications have a substantially higher cost than current first-line treatments, making it difficult for patients to access them.
A recent study found that adults with type 1 diabetes are at a high risk of being overweight or obese, but only half receive lifestyle recommendations to manage their weight. The study also highlighted the importance of individualized patient education in improving weight management for these patients.
Researchers from UTSA and UT Health San Antonio are developing compounds that target the estrogen receptor-beta, which suppresses cancer growth. The goal is to identify a novel ER-beta agonist with potential as a therapeutic strategy for treating GBM in patients.
A new preclinical study discovered the underlying cause of gender differences in immunotherapy-associated myocarditis and identified potential treatment strategies. Hormone therapies targeting the endocrine-cardiac-immune pathway may reduce this risk without affecting treatment efficacy.
A new approach combines an immunotherapy agent with a molecular delivery system that targets tumor acidity, successfully eradicating colorectal tumors in mice. The researchers believe this method may increase the effectiveness of STING agonist therapy for cancer patients.